Sequana Medical N.V.

Equities

SEQUA

BE0974340722

Biotechnology & Medical Research

Market Closed - Euronext Bruxelles 10:57:13 2024-04-26 am EDT 5-day change 1st Jan Change
1.39 EUR -0.71% Intraday chart for Sequana Medical N.V. -3.47% -65.25%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
Sequana Medical Announces Strong Data from DSR Proof-of-Concept Studies in Heart Failure Published in European Journal of Heart Failure CI
Sequana Medical NV Reports Earnings Results for the Full Year Ended December 31, 2023 CI
Sequana Medical NV Announces Three Month Follow-Up Data from MOJAVE Non- Randomized Cohort Confirming Significant Improvement in Diuretic Response and Virtual Elimination of Loop Diuretics Following DSR Therapy CI
Sequana Medical Raises EUR11.5 Million via Share Placement MT
Sequana Medical's Premarket Application for Alfapump Accepted by US FDA; Shares Rise MT
Sequana Medical Receives New US Reimbursement Codes for Alfapump System MT
Belgium's Sequana Medical Seeks US FDA Premarket Approval for Liver Ascites Treatment Device MT
Sequana Medical NV Announces Positive Data from Non- Randomized Cohort in US Phase 1/2a MOJAVE Study of DSR® 2.0 for Treatment of Heart Failure CI
Sequana Medical NV Appoints Ids Van Der Weij as Non-Executive Director CI
Certain Shares of Sequana Medical NV are subject to a Lock-Up Agreement Ending on 22-OCT-2023. CI
Transcript : Sequana Medical NV - Special Call
Sequana Medical NV Announces Initial Positive Data from MOJAVE, a US Phase 1/2A Study of DSR 2.0 for Treatment of Heart Failure through Breaking Vicious Cycle of Cardiorenal Syndrome CI
Sequana Medical NV Reports Earnings Results for the Half Year Ended June 30, 2023 CI
Transcript : Sequana Medical NV, H1 2023 Earnings Call, Sep 14, 2023
Belgium’s Sequana Medical Enrolls First Patient in Early-stage Trial for Treatment of Chronic Heart Failure MT
Sequana Medical NV Announces First Patient Enrolled in Mojave, a US Randomized Controlled Phase 1/2a Study of DSR 2.0 for Treatment of Compostive Heart Failure CI
Sequana Medical NV Announces Completion of 1,000th Alfapump Implant CI
Sequana Medical NV Appoints Kenneth Macleod as Non-Executive Director CI
Transcript : Sequana Medical NV - Special Call
Sequana Medical Secures US FDA Clearance for Investigational New Drug Application MT
Belgium's Sequana Medical Raises EUR16 Million to Advance Clinical Programs MT
Sequana Medical NV announced a financing transaction CI
Sequana Medical NV Announces Submission of Investigational New Drug Application for DSR® 2.0 for Treatment of Congestive Heart Failure CI
Sequana Medical Receives US, Chinese Patents for Direct Sodium Removal Program MT
Sequana Medical Announces Positive Results from Chihuahua, Phase 1 Clinical Trial of Second-Generation DSR Product for Congestive Heart Failure CI
Chart Sequana Medical N.V.
More charts
Sequana Medical N.V. is a commercial stage medical device company utilizing its proprietary alfapump® and DSR® (Direct Sodium Removal) technologies to develop innovative treatments for fluid overload in liver disease, malignant ascites and heart failure where diuretics are no longer effective. The alfapump is a fully-implanted, wireless device that automatically pumps fluid from the abdomen into the bladder, where it is removed naturally through urination. The alfapump is CE-marked for the management of refractory ascites due to liver cirrhosis and malignant ascites and has been granted breakthrough device designation by the US FDA with a North American pivotal study underway. DSR is a novel approach to manage sodium and fluid overload through use of a sodium-free infusate administered into the abdominal cavity. The alfapump DSR® combines DSR therapy with the proven alfapump platform and is in clinical development as potential treatment for decompensated heart failure patients.
Calendar
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
More Ratings
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
3
Last Close Price
1.39 EUR
Average target price
5.967 EUR
Spread / Average Target
+329.26%
Consensus
  1. Stock Market
  2. Equities
  3. SEQUA Stock
  4. News Sequana Medical N.V.
  5. Sequana Medical Raises EUR11.5 Million via Share Placement